Glossary · Research

WHI Study (2002 Women's Health Initiative)

Also called: WHI, Women's Health Initiative, 2002 WHI study, WHI 2002.

Definition: The WHI Study (Women's Health Initiative, 2002) was a large NIH-funded randomized trial of postmenopausal HRT whose mid-trial halt produced the 2002 headlines that drove a generational drop in HRT prescribing. Re-analyses since — including the 2022 BMJ paper — show the apparent risks were age-, route-, and progestin-dependent, with much more favorable outcomes when HRT is started within the timing window (within ~10 years of menopause onset).

Detailed definition

The Women's Health Initiative (WHI) was an NIH-funded study launched in 1993 with several arms, including two randomized HRT trials: oral conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day (CEE+MPA) in women with a uterus, and CEE alone in women without a uterus. The combined arm was halted in July 2002 when a pre-specified stopping criterion (breast cancer signal) was reached. Concurrent reports flagged small increases in stroke and venous thromboembolism. The estrogen-alone arm continued and ultimately showed favorable cardiovascular and breast-cancer outcomes in long-term follow-up.

The 2002 headlines drove a sharp drop in HRT prescribing — up to 70% globally within two years — and decades of patient avoidance. Subsequent re-analyses, including by WHI investigators themselves, showed that the apparent risks were heavily concentrated in older women starting HRT 10+ years after menopause; that the breast-cancer signal was driven primarily by the synthetic progestin (medroxyprogesterone acetate) rather than estrogen; and that women aged 50–59 actually had favorable cardiovascular and all-cause mortality outcomes. The 2022 BMJ re-analysis and the 2022 NAMS Position Statement reflect the modernized interpretation. The 2024 NAMS Hormone Therapy Position Statement explicitly walked back the most cautionary 2002 framing.

Why it matters in menopause

The 2002 WHI is the single most consequential data point in the history of menopause care — not because of what it showed, but because of how badly its headlines were misinterpreted. Modern HRT (transdermal bioidentical estradiol plus bioidentical micronized progesterone, started in the timing window) is a clinically distinct intervention from what WHI studied (oral CEE plus synthetic MPA, in older women, with a wide age range). Modern guidance from NAMS, ACOG, the Endocrine Society, and the International Menopause Society reflects this distinction. ClearedRx clinicians explain the WHI context to patients hesitant about HRT, and the 2022 BMJ paper is now standard reading in modern menopause training.

The modern takeaway

For symptomatic women under 60 (or within 10 years of menopause onset) without contraindications, HRT's benefits typically outweigh its risks. Risk varies by route (transdermal estradiol has lower VTE/stroke risk than oral CEE), by progestogen choice (micronized progesterone has a more favorable breast and cardiovascular profile than MPA), and by individual factors. The 2002 WHI was a single data point, not a verdict. Decisions in 2026 should be made on 2026 evidence.

Sources

External references: Wikipedia: Women's Health Initiative.

← Back to full glossary